Portal de Periódicos da CAPES

Management of Fulminating Ulcerative Colitis in Childhood with Chimeric Anti-CD25 Antibody

2006; Lippincott Williams & Wilkins; Volume: 42; Issue: 2 Linguagem: Inglês

10.1097/01.mpg.0000189347.32796.c5

1536-4801

A. Schwarzer, Ida Ricciardelli, Sian Kirkham, K Binnie, Neha Shah, Mamoun Elawad, Simon Hill, Mark Furman, V. V. Smith, Neil J. Sebire, P J Milla, Marco Londei, Keith Lindley,

Immunodeficiency and Autoimmune Disorders

ABSTRACT Fulminating acute ulcerative colitis (UC) is a potentially life threatening medical emergency. Up to 30% of individuals respond poorly to corticosteroids alone and second line medical or surgical therapies are indicated. We describe the successful use of chimeric anti‐CD25 therapy in 4 such children poorly responsive to combined therapy with intravenous steroids and calcineurin inhibitors with a pretreatment predictive risk of colectomy of 85‐100%. Clinical disease activity scores normalized within 72 hours of anti‐CD25 administration and colonic histology provided evidence of mucosal healing within 10‐14 days. None required emergency colectomy. Anti‐CD25 is efficacious in fulminating UC and randomized placebo controlled trials appear indicated.